Print Locations, travel and lodgingMayo Clinic has major campuses in Phoenix and Scottsdale, Arizona; Jacksonville, Florida; and Rochester, Minnesota. The Mayo Clinic Health System has dozens of locations in several states. For more information on visiting Mayo Clinic, choose your location below: Mayo Clinic's campus in Arizona Mayo Clinic's campus in Florida Mayo Clinic's campus in Minnesota Mayo Clinic Health System Mayo Clinic Healthcare, located in London Costs and insuranceMayo Clinic works with hundreds of insurance companies and is an in-network provider for millions of people. In most cases, Mayo Clinic doesn't require a physician referral. Some insurers require referrals or may have additional requirements for certain medical care. All appointments are prioritized on the basis of medical need. Learn more about appointments at Mayo Clinic. Please contact your insurance company to verify medical coverage and to obtain any needed authorization prior to your visit. Often, your insurer's customer service number is printed on the back of your insurance card. More information about billing and insurance: Mayo Clinic in Arizona, Florida and Minnesota Mayo Clinic Health System By Mayo Clinic Staff Request an appointment About Sept. 05, 2026 PrintShow references FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer. U.S. Food and Drug Administration. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line. Accessed Aug. 4, 2026. Immunotherapy for breast cancer. National Cancer Institute. https://www.cancer.gov/types/breast/treatment/immunotherapy. Accessed Aug. 4, 2026. Schmid P, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. New England Journal of Medicine. 2024; doi:10.1056/NEJMoa2409932. Heater NK, et al. Current and future immunotherapy for breast cancer. Journal of Hematology & Oncology. 2024; doi:10.1186/s13045-024-01649-z. Immune checkpoint inhibitors. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors. Accessed Aug. 4, 2026. Cortes J, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. New England Journal of Medicine. 2022; doi:10.1056/NEJMoa2202809. Raghavendra AS, et al. Breast cancer brain metastasis: A comprehensive review. JCO Oncology Practice. 2024; doi:10.1200/OP.23.00794. Villacampa G, et al. Neoadjuvant immune checkpoint inhibitors plus chemotherapy in early breast cancer: A systematic review and meta-analysis. JAMA Oncology. 2024; doi:10.1001/jamaoncol.2024.3456. Verma S, et al. Immunotherapy and radiation therapy sequencing in breast cancer: A systematic review. International Journal of Radiation Oncology, Biology, Physics. 2024; doi:10.1016/j.ijrobp.2024.01.001. Madsen AMH, et al. Targeted treatment of metastatic triple-negative breast cancer: A systematic review. The Breast Journal. 2024; doi:10.1155/2024/9083055. Chemotherapy for breast cancer. National Cancer Institute. https://www.cancer.gov/types/breast/treatment/chemotherapy. Accessed Aug. 5, 2026. Medical review (expert opinion). Mayo Clinic. Sept. 2, 2026. Related Breast cancer Immunotherapy for breast cancerAboutCare atMayoClinic PRC-20605578 Tests & Procedures Breast cancer immunotherapy